Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20773002 | 0.82 | MAPT (0.62) | RXFP1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20772616 | 0.80 | RXRA (0.57) | MRGPRX4HPGDPTGER1 | |
| SCHEMBL16239959 | 0.79 | KDM4E (0.71) | MRGPRX4HDAC6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16239902 | 0.79 | HDAC6 (0.56) | MRGPRX4HDAC6LMNAMEN1KMT2A | |
| SCHEMBL366812 | 0.78 | MAOB (0.63) | RXFP1LMNAMEN1KMT2AMAPT | |
| SCHEMBL20773035 | 0.76 | SMPD1 (0.58) | MRGPRX4MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL28410264 | 0.74 | SCN9A (0.48) | MRGPRX4RXFP1LMNAMEN1KMT2A | |
| SCHEMBL680720 | 0.74 | EZH2 (0.58) | MRGPRX4HDAC6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14892906 | 0.74 | HDAC6 (0.51) | MRGPRX4RXFP1HDAC6LMNAKMT2A | |
| SCHEMBL20772786 | 0.73 | SCN9A (0.42) | MRGPRX4BCL2L1MCL1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3676248-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-07-08 | — | — | EP | disclosed |
| CN-111132961-A | Bisaryloxy derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| WO-2019045035-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | SCN1B, SCN3A, SCN2B | MRGPRX4 1461/4885RXFP1 3573/4885HDAC6 294/4885 |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN3A, SCN2B | MRGPRX4 1461/4885RXFP1 3573/4885HDAC6 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.